SELECT THE REQUIRED INFORMATION

PROFESSIONAL INFORMATION

PATIENT INFORMATION LEAFLET

Bayer (Pty) Ltd	**Date of revision of text: 19 December 2021 (storage conditions)**

PATIENT INFORMATION LEAFLET

SCHEDULING STATUS: S4

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:

MAGNEVIST

0,5 mmol gadopentetate dimeglumine

Solution

Read all of this leaflet carefully before you are given MAGNEVIST.

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or radiologist or your pharmacist.

1. WHAT MAGNEVIST CONTAINS:

The active substance is 0,5 mmol gadopentetate dimeglumine (equivalent to 469,01 mg gadopentetate dimeglumine).

The other ingredients are meglumine, pentetic acid and water for injections.

2. WHAT MAGNEVIST IS USED FOR:

MAGNEVIST is a contrast medium for magnetic resonance imaging (MRI) of the brain, spine, vessels and other body regions.
This medicine is provided as a solution for injection into a vein only. It is for diagnostic use, only.
MRI is a form of medical diagnostic imaging that forms pictures after water molecules have been detected in normal and abnormal tissues. This is done by a complex system of magnets and radio waves. Computers record the activity and translate that into images.

3. BEFORE YOU ARE GIVEN MAGNEVIST:

You should not receive MAGNEVIST:

If you have severely compromised kidney malfunction.
Safety in pregnancy and lactation has not been established.
Tell your doctor, before receiving MAGNEVIST, if you think this may apply to you.

Take special care with MAGNEVIST:

Fatal reactions have been associated with the administration of water-soluble contrast media such as MAGNEVIST. You will be observed during and for at least 30 to 60 minutes after administration of MAGNEVIST, especially if you have previously had a hypersensitivity reaction to contrast media containing iodine.

Allergy-like hypersensitivity reactions involving the heart, breathing or the skin, may occur with the use of MAGNEVIST. Severe reactions including shock are possible. Most of these reactions occur within

at least half an hour of administration. However, in rare cases delayed reactions (after hours to days) may occur (see "Possible side effects").

Before you receive MAGNEVIST **tell your doctor, the radiologist or MRI centre if any of the conditions listed below applies to you**. Your doctor will decide whether the intended examination is possible or not.

- if you are allergic (hypersensitive) to gadopentetate dimeglumine or any of the other ingredients of MAGNEVIST;
- if you have or have had allergy (e.g., hay fever, hives) or asthma;
- if you had a previous reaction to contrast media;
- if you suffer from heart or blood circulation problems. This is because in the rare event that you have an allergic reaction, it is more likely to be serious or fatal;
- if you have a very poor kidney function;
- if you have epilepsy or suffer from brain conditions with seizures or from other lesions of the brain. Fits or seizures have occurred rarely in patients with similar conditions;
- if you have recently had or soon expect to have a liver transplant.

Tell your doctor, the radiologist or MRI centre staff if you have a heart pacemaker or if there are any implants or clips containing iron in your body.

Before you have any blood tests, tell your doctor you have been given MAGNEVIST. This is because some tests for iron levels in the blood may be affected for up to 24 hours after MAGNEVIST has been given.

Children and adolescents:

With the exception of the brain and spine examinations there is limited experience for using MAGNEVIST in patients younger than two years.
In newborns and infants the required dose should be administered by hand.

Kidney impairment:

- Before you receive MAGNEVIST, **your doctor will check how well your kidneys are working.** Your doctor may decide to take a blood test to check this before making the decision to use MAGNEVIST.

If you have a poor kidney function, the doctor will make sure that MAGNEVIST has been eliminated from your body before you receive a second injection of MAGNEVIST.
MAGNEVIST can be removed from the body by dialysis. If you are already undergoing regular dialysis, your doctor will give a recommendation when to schedule the next dialysis.
There have been reports of a severe reaction, mainly involving a thickening of the skin and connective tissues (nephrogenic systemic fibrosis (NSF)). NSF may result in severe joint immobility, muscle weakness or may affect the normal working of internal organs which may potentially be life-threatening.
NSF has been associated with the use of some contrast agents containing gadolinium including MAGNEVIST in patients with severe kidney impairment.
It has also been associated with the use of some contrast agents containing gadolinium including MAGNEVIST in patients with acute kidney insufficiency due to the hepato-renal syndrome (kidney failure in patients with advanced chronic liver disease) or in patients with acute kidney insufficiency, who have recently had or soon expect to have a liver transplant (see "Possible side effects").

Using MAGNEVIST with food and drink:

MAGNEVIST can cause nausea and vomiting. You will therefore be asked not to eat anything for 2 hours before the examination.

Pregnancy and breastfeeding:

If you are pregnant or breastfeeding your baby, please consult your doctor, pharmacist or other healthcare professional for advice.

Tell your doctor, the radiologist or the MRI centre staff if you are pregnant or could be pregnant, since the safe use of MAGNEVIST during pregnancy has not yet been demonstrated. MAGNEVIST should only be used in pregnancy after a thorough benefit/risk assessment.

Tell your doctor if you are breastfeeding or intend to breastfeed. The safe use of MAGNEVIST during breastfeeding has not yet been established. However, minimal amounts of MAGNEVIST (a maximum of 0,04 % of the administered dose) enter the breast milk. From experience gained so far, harm to the breastfed infant is not likely.

Using other medicines with MAGNEVIST:

If you are taking other medicines on a regular basis, including complementary or traditional medicines, the use of MAGNEVIST with these medicines may cause undesirable interactions. Please consult your doctor, pharmacist or other healthcare professional, for advice.

Tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Inform your doctor specifically if you are taking beta blockers (medication for treating hypertension or irregular heartbeat).

4. HOW YOU WILL BE GIVEN MAGNEVIST:

MAGNEVIST is injected by a doctor via a needle or catheter into a vein. Your MRI examination can start immediately.
The dose of MAGNEVIST that is right for you will depend on your bodyweight:
A single injection of 0,2 ml MAGNEVIST per kg bodyweight is generally sufficient (this means for a person weighing 70 kg the dose would be 14 millilitres).
In special cases, this may be increased in adults to 0,6 ml per kilogram bodyweight and in children to 0,4 ml per kilogram bodyweight at maximum as a single dose. The radiologist will decide how much MAGNEVIST is needed for your investigation.
With the exception of the brain and spine examinations there is limited experience for using MAGNEVIST in patients younger than two years.

If you have a severe disturbance of kidney function or an acute kidney insufficiency, a total amount of 0,2 ml MAGNEVIST per kg bodyweight should be administered at maximum. Your doctor or radiologist will decide whether the intended examination is possible or not.

Sufficient period of time for elimination of the contrast agent from the body prior to any re-administration should be ensured. Your doctor will decide whether the intended examination is possible or not.

If you receive more MAGNEVIST than you should:

Overdosing is unlikely. If it does happen, the doctor will treat any symptoms that follow. If your kidneys do not work properly, your doctor will check the kidney function in case of overdose.

5. POSSIBLE SIDE EFFECTS:

Not all side effects reported for MAGNEVIST are included in this leaflet. Should your general health worsen while using MAGNEVIST, please consult your doctor, pharmacist or other healthcare professional for advice.

MAGNEVIST can cause side effects.

Side effects associated with the use of MAGNEVIST are usually mild to moderate and transient in nature. Delayed reactions and severe and life-threatening reactions as well as deaths have been reported.

The most frequently observed side effects in patients receiving MAGNEVIST (may affect 4 or more in a 1000 users) are various injection site reactions, headache and nausea (feeling sick).

The most serious side effects in patients receiving MAGNEVIST are nephrogenic systemic fibrosis (NSF) and anaphylactoid reactions (allergy-like reactions) including severe reactions such as shock. NSF is a severe reaction, mainly involving a thickening of the skin and connective tissues, and may result in severe joint immobility, muscle weakness or may affect the normal working of internal organs which may potentially be life-threatening.

Allergy-like reactions may occur including severe reactions such as shock that may need immediate medical intervention. If you notice mild swelling of the face, lips, tongue or throat, coughing or sneezing, difficulty in breathing, itching, runny nose or hives (nettle-type rash), **tell your doctor, the radiologist or MRI staff immediately**. These may be the first signs that a severe reaction is happening. Your investigation may need to be stopped, and you may need further treatment.

Delayed reactions hours to several days after the administration of MAGNEVIST, have been observed. If this should happen to you tell your doctor or radiologist.

Below the reported/experienced side effects are listed by frequency.
Less frequent:

- headache, dizziness, dysgeusia (disturbed sense of taste)
- vomiting (being sick), nausea (feeling sick)
- pain, feeling hot, feeling cold
- sensations or reactions at the injection site such as:
  coldness, paraesthesia (“pins and needles”), swelling, warmth, pain, oedema, irritation, haemorrhage (bleeding), erythema (reddish painful skin), discomfort, necrosis (death of tissue), thrombophlebitis (inflammation of a vein caused by or associated with a blood clot), phlebitis (inflammation of a vein), inflammation, extravasation (bleeding into the tissue at the injection site), pain, bruising, change in skin colour
- hypersensitivity (allergy)/anaphylactoid (allergy-like) reactions, e.g. anaphylactoid shock (severe allergy-like reaction); shock (circulatory collapse); hypotension (low blood pressure); conjunctivitis; loss of consciousness; throat tightness; sneezing; urticaria (hives, nettle-type rash); pruritus (severe itching); rash; erythema (redness of the skin); dyspnoea (difficulty in breathing);

respiratory arrest (stopped breathing); bronchospasm (difficulty in breathing); wheezing; laryngospasm (voice box spasm); laryngeal oedema (voice box oedema); pharyngeal oedema (swelling of the throat); cyanosis (blue lips); rhinitis (runny nose); angioedema (e.g. swelling of the face, throat, mouth, lips and/or tongue); face oedema (swelling of the face); reflex tachycardia (abnormally fast heartbeat)
- disorientation
- convulsion (fits or seizures); paraesthesia (numbness and tingling); burning sensation; tremor
- tachycardia (abnormally fast heartbeat); arrhythmia (irregular heartbeat)
- thrombophlebitis (inflammation of a vein caused by or associated with a blood clot); flushing; vasodilatation (widening of blood vessels)
- throat irritation; pharyngolaryngeal pain/pharynx discomfort (pain or discomfort in the throat); coughing
- stomach (abdominal) pain or discomfort; diarrhoea; toothache; dry mouth; oral soft tissue pain and paraesthesia (pains or numbness and tingling in the mouth)
- pain in arms, hands, legs and feet (extremities)
- chest pain; fever; swelling of the arms, hands, legs and feet (oedema peripheral); generally feeling unwell (malaise); tiredness (fatigue); thirst; weakness (asthenia)

In patients with dialysis-dependent kidney failure who received MAGNEVIST, delayed and passing inflammatory-like reactions such as fever, chills and C-reactive protein increase (a blood test marker for inflammatory reactions) have been commonly observed. These patients had the MRI examination with MAGNEVIST on the day before haemodialysis.

The following side effects have been life-threatening or fatal in some cases: nephrogenic systemic fibrosis (NSF; a severe reaction, mainly involving a thickening of the skin and connective tissues), anaphylactoid shock (severe allergy-like reaction), anaphylactoid (allergy-like) reaction, hypersensitivity reactions (allergy), shock (circulatory collapse), hypotension (low blood pressure), loss of consciousness, throat tightness, dyspnoea (difficulty in breathing), respiratory arrest (stopped breathing), bronchospasm (difficulty in breathing), laryngospasm (voice box spasm), laryngeal oedema (voice box oedema), pharyngeal oedema (swelling of the throat), cyanosis (blue lips), angioedema (e.g. swelling of the face, throat, mouth, lips and/or tongue), face oedema (swelling of the face), convulsion (fits or seizures), tachycardia (abnormally fast heart beat), increased serum iron, coma, somnolence (sleepiness), cardiac arrest (sudden stopping of the heart), bradycardia (decreased heart rate), syncope (fainting) and pulmonary oedema (fluid in the lungs).

- **Tell the department staff immediately if you experience any difficulty in breathing.**
- **If any of the side effects gets serious,** or if you notice any side effects not listed in this leaflet, please tell your doctor or radiologist.

6. STORING AND DISPOSING OF MAGNEVIST:

KEEP ALL MEDICINES OUT OF THE REACH AND SIGHT OF CHILDREN.
Until required for use, MAGNEVIST must be stored in the original outer carton at or below 30 °C.
Protect from light.
Do not use after the expiry date stated on the carton and the container label.
Do not dispose of unused medicine in drains or sewerage systems (e.g., toilets).

7. PRESENTATION OF MAGNEVIST:

Clear glass vials of 5, 10, 15, 20 or 30 ml packed in a carton containing 10 vials.

Clear glass prefilled syringes of 10, 15 or 20 ml packed in a carton containing 5 prefilled syringes.
Clear glass bottles of 100 ml for use with an automatic injector packed in a carton containing 10 bottles.

8. IDENTIFICATION OF MAGNEVIST:

Clear, sterile, pyrogen-free aqueous solution.

9. REGISTRATION NUMBERS:

MAGNEVIST 5 ml	28/28/0639
MAGNEVIST 10 ml:	28/28/0640
MAGNEVIST 15 ml:	28/28/0641
MAGNEVIST 20 ml:	W/28/0199
MAGNEVIST 30 ml:	36/28/0026
MAGNEVIST 100 ml:	36/28/0027

10. NAME AND ADDRESS OF REGISTRATION HOLDER:

Bayer (Pty) Ltd
Reg. No.: 1968/011192/07
27 Wrench Road
ISANDO
1609

11. DATE OF PUBLICATION:

19 April 2013